

Susanne Sauãele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7351781/publications.pdf>

Version: 2024-02-01

35
papers

3,422
citations

430442

18
h-index

395343

33
g-index

35
all docs

35
docs citations

35
times ranked

3217
citing authors

#	ARTICLE	IF	CITATIONS
1	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
2	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology</i> , The, 2018, 19, 747-757.	5.1	444
3	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. <i>Journal of Clinical Oncology</i> , 2014, 32, 415-423.	0.8	271
4	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	0.6	147
5	Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 945-954.	1.2	124
6	Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2821-2823.	0.8	122
7	Chronic myeloid leukaemia. <i>Lancet</i> , The, 2021, 398, 1914-1926.	6.3	65
8	Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. <i>Annals of Hematology</i> , 2014, 93, 71-80.	0.8	60
9	Management of CML-blast crisis. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 295-307.	0.7	60
10	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. <i>Leukemia</i> , 2020, 34, 2125-2137.	3.3	47
11	The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis. <i>Haematologica</i> , 2020, 105, 136-147.	1.7	44
12	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. <i>Leukemia</i> , 2021, 35, 1344-1355.	3.3	43
13	Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. <i>Acta Haematologica</i> , 2020, 143, 217-231.	0.7	26
14	Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. <i>Leukemia</i> , 2018, 32, 1222-1228.	3.3	22
15	Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. <i>Leukemia</i> , 2020, 34, 2113-2124.	3.3	22
16	Older patients with chronic myeloid leukemia (>65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. <i>Annals of Hematology</i> , 2014, 93, 1167-1176.	0.8	21
17	DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1177.	1.8	20
18	Efficacy and Safety Results from ASCSEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	ARTICLE	IF	CITATIONS
19	Effect of ABCG2 , OCT1 , and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 266-271.	0.2	18
20	Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. <i>Cancer Research</i> , 2018, 78, 6223-6234.	0.4	16
21	Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. <i>PLoS ONE</i> , 2019, 14, e0214305.	1.1	16
22	Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMRâ€”final report from AFTER-SKI. <i>Leukemia</i> , 2021, 35, 2416-2418.	3.3	13
23	FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study. <i>Blood</i> , 2021, 138, 633-633.	0.6	10
24	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. <i>Leukemia</i> , 2022, 36, 1834-1842.	3.3	10
25	Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV. <i>Blood</i> , 2008, 112, 184-184.	0.6	8
26	The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia. <i>PLoS ONE</i> , 2018, 13, e0196326.	1.1	7
27	Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases. <i>Annals of Hematology</i> , 2022, 101, 1825-1834.	0.8	7
28	Clinical Trials in Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 109-115.	1.2	3
29	Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020, 99, 991-1006.	0.8	3
30	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV. <i>Blood</i> , 2008, 112, 448-448.	0.6	3
31	Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1647-1647.	0.6	3
32	Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response. <i>Blood</i> , 2021, 138, 3608-3608.	0.6	3
33	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. <i>Blood</i> , 2021, 138, 1476-1476.	0.6	1
34	Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response. <i>Hematologic Malignancies</i> , 2021, , 265-273.	0.2	0
35	Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7551-7551.	0.8	0